Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety, and Tolerability of Exenatide Once-Weekly Suspension in Chinese Patients With T2DM
NCT04001231Phase 1Withdrawn
- Sponsor
- AstraZeneca
- Start
- Jun 2020
- Primary completion
- Jul 2021
- Modality
- Peptides
01
Overview
Phase 1, open-label, single-arm trial of exenatide in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Primary endpoints: Plasma concentrations versus time profile of exenatide, Maximum observed plasma concentration and 11 more. Planned start Jun 2020; status: withdrawn.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04001231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04001231.